Yichuan Xia
Overview
Explore the profile of Yichuan Xia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spira A, Paz-Ares L, Han J, Shih J, Mascaux C, Roy U, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864547
Introduction: Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced NSCLC as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related...
2.
Quattrin T, Haller M, Steck A, Felner E, Li Y, Xia Y, et al.
N Engl J Med
. 2020 Nov;
383(21):2007-2017.
PMID: 33207093
Background: Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor that has already...
3.
Kollmeier A, Francke K, Chen B, Dunford P, Greenspan A, Xia Y, et al.
J Pharmacol Exp Ther
. 2014 May;
350(1):181-7.
PMID: 24817035
The histamine H4 receptor (H4R) is a promising target for the treatment of pruritus. A clinical study was conducted to evaluate the safety and efficacy of the H4R antagonist, JNJ...
4.
Griffiths C, Strober B, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al.
N Engl J Med
. 2010 Jan;
362(2):118-28.
PMID: 20071701
Background: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic...